Atsena Therapeutics recently announced that the ﬁrst patient has been dosed in the phase 3 LIGHTHOUSE trial evaluating ATSN-201 for the treatment of x-linked retinoschisis (XLRS).

ATSN-201 - Atsena Therap

Jul 4, 2026